Increasing evidence suggests that superantigens play a role in Immune-mediated diseases. Superantigens are potent activators of CD4* T cells, causing rapid and massive proliferation of cells and cytokine production. This characteristic of superantigens can be exploited in diseases where strong immunologic responses are required, such as in the B16F10 animal model of melanoma. Superantigen administration is able to significantly enhance Ineffective anti-tumor Immune responses, resulting in potent and long-lived protective anti-tumor immunity. However, superantigens are more well-known for the role they play in diseases. Studies using an animal model for neurologic demy-elinatlng diseases such as multiple sclerosis show that superantigens can induce severe relapses and activate auto-reactive T cells not involved in the Initial bout of disease. This may also involve epitope spreading of disease. Superantigens have also been implicated in acute diseases such as food poisoning and TSS, and in chronic diseases such as psoriasis and rheumatoid arthritis. Viral superantigens are also involved in the disease process, including superantigens derived from human Immunodeficiency virus and mouse mammary tumor virus. Finally, immunotherapies that ameliorate the role played by superantigens in disease are discussed.
JohnsonHM, TorresBA, SoosJM. Superantigens in human disease. Proc Soc Exp Biol Med212: 99–109, 1994.
3.
BergdollMS. The staphylococcal enterotoxins—an update. In: JelaszewicsJ, Ed. The staphylococci. New York: Gustav Fisher Verlag, pp 247–266, 1985.
4.
SchiffenbauerJ, JohnsonHM, ButfiloskiE, WegrzynL, SoosJM. Staphylococcal enterotoxins reactivate experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A90: 8543–8546, 1993.
5.
SoosJM, HobeikaAC, ButfiloskiEJ, SchiffenbauerJ, JohnsonHM. Accelerated induction of experimental allergic encephalomyelitis in PL/J mice by a non-Vβ8-speciflc superantigen. Proc Natl Acad Sci U S A92: 6082–6086, 1995.
6.
AbeJ, KotzinBL, JujoK, MelishME, GlodeMP, KohsakaT, LeungDYM.Selective expansion of T cells expressing T cell receptor variable region Vβ2 and Vβ8 in Kawasaki's disease. Proc Natl Acad Sci USA89: 4066–4070, 1992.
7.
KotzinBL, LeungDYM, KapplerJ, MarrackP.Superantigens and their potential role in human disease. Adv Immunol54: 99–166, 1993.
8.
HoferMF, HarbeckRJ, SchlievertPM, LeungDYM.Staphylococcal toxins augment specific IgE responses by atopic patients exposed to allergen. J Invest Dermatol112: 171–176, 1999.
9.
LeungDY, TraversJB, GiornoR, NorrisDA, SkinnerR, AelionJ, KazemiLV, KimMH, TrumbleAE, KotbM, SchlievertPM. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest96: 2106–2112, 1995.
10.
ColeBC, GriffithsMM. Triggering and exacerbation of autoimmune arthritis by the Mycoplasma arthriditis superantigen MAM. Arth Rheum36: 994–1002, 1993.
11.
OhmenJD, BarnesPF, GrissoCL, BloomBR, ModlinRL. Evidence for a superantigen in human tuberculosis. Immunity1: 35–43, 1994.
12.
UchiyamaT, Miyoshi-AkiyamaT, KatoH, FujimakiW, ImanishiK, YanX.Superantigenic properties of a novel mitogenic substance produced by Yersinia pseudotuberculosis isolated from patients manifesting acute and systemic symptoms. J Immunol151: 4407–4413, 1993.
13.
LeungKP, TorresBA. Prevotella intermedia stimulates the expansion of Vβ specific CD4+ T cells. Infect Immun68: 5420–5424, 2000.
14.
HeldW, Acha-OrbeaH, MacDonaldHR, WaandersGA. Superantigens and retroviral infection: Insights from mouse mammary tumor virus. Immunol Today15: 184–190, 1994.
15.
HuginAW, VacchioMS, MorseHCIII. A virus-encoded “superantigen” in a retrovirus-induced immunodeficiency syndrome of mice. Science252: 424–427, 1991.
16.
ConradB, WeidmannE, TruccoG, RudertWA, BehbooR, RicordiC, Rodriquez-RiloH, FinegoldD, TruccoM.Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature371: 351–355, 1994.
17.
ConradB, WeissmahrRN, BoniJ, ArcariR, SchupbachJ, MachB.A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell90: 303–313, 1997.
18.
TorresBA, TanabeT, YamamotoJK, JohnsonHM. HIV encodes for its own CD4 T cell superantigen mitogen. Biochem Biophys Res Commun225: 672–678, 1996.
19.
LafonM, GalleliA.Superantigen related to rabies. Springer Semin Immunopathol17: 307–318, 1996.
20.
LafonM, LafargeM, Martinez-ArendsA, RamirezR, VuillerF, CharronD, LotteauV, Scott-AlgaraD.Evidence for a viral superantigen in humans. Nature358: 507–510, 1992.
MollickJA, CookRG, RichRR. Class II MHC molecules are specific receptors for staphylococcal enterotoxin A. Science244: 817–820, 1989.
23.
WrightAD, ChapesSK. Cross-linking of staphylococcal enterotoxin A bound to major histocompatibility complex class I is required for TNF-α secretion. Cell Immunol197: 129–135, 1999.
24.
D'orazioJA, Stein-StreileinJ.Human natural kitler (NK) cells present staphylococcal enterotoxin B (SEB) to T lymphocytes. Clin Exp Immunol104: 366–373, 1996.
25.
RussellJK, PontzerCH, JohnsonHM. The I-Aβb region (65-85) is a binding site for the superantigen staphylococcal enterotoxin A. Biochem Biopys Res Commun168: 696–701, 1990.
26.
RussellJK, PontzerCH, JohnsonHM. Both α-helices along the major histocompatibility complex binding cleft are required for staphylococcal enterotoxin A function. Proc Natl Acad Sci U S A88: 7228–7232, 1991.
27.
CallahanJE, HermanA, KapplerJ, MarrackP.Stimulation of B110.BR T cells with superantigenic staphylococcal enterotoxins. J Immunol144: 2473–2479, 1990.
28.
MarrackP, KapplerJ.The staphylococcal enterotoxins and their relatives. Science248: 705–711, 1990.
29.
PeavyDL, AdlerWH, SmithRT. Mitogenic effects of endotoxin and SEB on mouse spleen cells and human lymphocytes. J Immunol105: 1453–1458, 1970.
30.
LangfordMP, StantonGJ, JohnsonHM. Biological effects of staphylococcal enterotoxin A on human peripheral lymphocytes. Infect Immun22: 62–68, 1978.
31.
CarlssonR, SjogrenHO. Kinetics of IL-2 and IFNγ production, expression of IL-2 receptors, and cell proliferation in human mononuclear cells exposed to SEA. Cell Immunol96: 175–183, 1985.
32.
JohnsonHM, MagazineHI. Potent mitogenic activity of staphylococcal enterotoxin A requires induction of interleukin 2. Int Arch Allergy Appl Immunol87: 87–90, 1988.
33.
SmithBG, JohnsonHM. The effect of staphylococcal enterotoxins on the primary in vitro immune response. J Immunol115: 575–578, 1975.
34.
KawabeY, OchiA.Selective anergy of V beta 8+,CD4+ T cells in Staphylococcus enterotoxin B-primed mice. J Exp Med172: 1065–1070, 1990.
35.
MahlknechtU, HerterM, HoffmannMK, NiethammerD, DanneckerGE. The toxic shock syndrome toxin-1 induces anergy in human T cells in vivo. Hum Immunol45: 42–45, 1996.
36.
HobeikaAC, EtienneW, CruzP, SubramaniamPS, JohnsonHM. IFN-γ induction of p21WAFI in prostate cancer cells: Role in cell cycle, alteration of phenotype and invasive potential. Int J Cancer77: 138–145, 1998.
37.
KominskySL, JohnsonHM, BryanG, TanabeT, HobeikaAC, SubramaniamPS, TorresBA. IFN-γ inhibition of cell growth in glioblastomas correlates with increased levels of p21WAFI/cIpI. Oncogene17: 2973–2979, 1998.
38.
HobeikaAC, EtienneW, TorresBA, JohnsonHM, SubramaniamPS. IFN-γ induction of p21WAFI is required for cell cycle inhibition and suppression of apoptosis. J Interferon Cytokine Res19: 1351–1361, 1999.
39.
MondJJ, LeesA, SnapperCM. T cell-independent antigens type 2. Annu Rev Immunol13: 655–692, 1995.
40.
ShrayerDP, KouttabN, HearingVJ, WaneboHJ. Immunization of mice with melanoma cells transfected to secrete the superantigen, staphylococcal enterotxin A. Cancer Immunol Immunother46: 7–13, 1998.
41.
DowSW, ElmslieRE, WilsonAP, RocheL, GormanC, PotterTA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest101: 2406–2414, 1998.
42.
WahlstenJL, MillsCD, RamakrishnanS.Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. J Immunol161: 6761–6767, 1998.
43.
TordssonJM, OhlssonLG, AbrahmsénLB, KarlströmPJ, LandoPA, BrodinTN. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. Cancer Immunol Immunother48: 691–702, 2000.
44.
NewtonDW, DohlstenM, LandoPA, KallandT, OlssonC, KotbM.MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: Implications for use in treatment of human colon carcinoma. Int J Mol Med1: 157–62, 1998.
45.
ScheuberPH, DenzlingerC, WilkerD, BeckG, KepplerD, HammerDK. Staphylococcal enterotoxin B as a nonimmunological mast cell stimulus in primates: The role of endogenous cysteinyl leukotrienes. Int Arch Allergy Appl Immunol82: 289–291, 1987.
46.
JettM, BrinkleyW, NeillR, GemskiP, HuntR.Staphylococcus aureus enterotoxin B challenge of monkeys: Correlation of plasma levels of arachidonic acid cascade proteins with occurrences of illness. Infect Immun58: 3494–3499, 1990.
47.
DimitriadouV, MecheriS, KoutsilierisM, FraserW, Al-DaccakR, MouradW.Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells. J Leukoc Biol64: 791–799, 1998.
48.
PoncetP, ArockM, DavidB.MHC class II-dependent activation of CD4+ T cell hybridomas by human mast cells through superantigen presentation. J Leukoc Biol66: 105–112, 1999.
Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. Morbid Mortal Weekly Rep46:1–55, 1997.
52.
BergdollMS, CrassBA, ReiserRF, RobbinsRN, DavisPJ. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic shock syndrome Staphylococcus aureus isolates. Lanceti:1017–1021, 1981.
53.
SchlievertPM, ShandsKN, DanBB, SchmidGP, NishimuraND. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis143: 509–516, 1981.
54.
AltemeierWA, LewisSA, SchievertPM, BergdollMS, BjomsonHJ, TaneckL, CrasssBA. Staphylococcus aureus associated with toxic shock syndrome: Phage typing and toxin capability tested. Ann Intern Med96: 978–982, 1982.
TraceyKJ, BeutlerB, LowrySF, MerryweatherJ, WolpeS, MilsarkJW, HaririRJ, FaheyTJ, ZentellaA, AlbertsJD. Shock and tissue injury induced by recombinant human cachectin. Science234: 470–474, 1986.
57.
BeutlerB, CeramiA.Cachectin: More than a tumor necrosis factor. N Engl J Med316: 379–385, 1987.
58.
ParsonnetJ.Mediators in the pathogenesis of toxic shock syndrome: Overview. Rev Infect Dis11(Suppl 1):S263–S269, 1989.
59.
SchiffenbauerJ, SoosJM, JohnsonHM. The possible role of bacterial superantigens in the pathogenesis of autoimmune disorders. Immunol Today19: 117–120, 1998.
60.
ZamvilSS, SteinmanL.The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol8: 579–621, 1990.
SchiffenbauerJ, JohnsonHM, ButfiloskiE, WegrzynL, SoosJM. Staphylococcal enterotoxins reactivate experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A90: 8543–8546, 1993.
63.
BrockeS, GaurA, PiercyC, GautamA, GijbelsK, FathmanCG, SteinmanL.Induction of relapsing paralysis in experimental allergic encephalomyelitis by bacterial superantigen. Nature365: 642–644, 1993.
64.
MatsumotoY, FujiwaraM.Immunomodulation of experimental autoimmune encephalomyelitis by staphylococcal enterotoxin D. Cell Immunol149: 268–278, 1993.
65.
KaimanB, LublinFD, LattimeE, JosephJ, KnoblerRL. Effects of staphylococcal enterotoxin B on T cell receptor Vβ utilization and clinical manifestations of experimental allergic encephalomyelitis. J Neuroimmunol45: 83–88, 1993.
66.
SoosJM, SchiffenbauerJ, JohnsonHM. Treatment of PL/J mice with the superantigen, staphylococcal enterotoxin B, prevents development of experimental allergic encephalomyelitis. J Neuroimmunol43: 39–43, 1993.
67.
JorensPG, VanderBorghtA, CeulemansB, Van BeverHP, BossaertLL, IevenM, GoossensH, ParizelPM, Van DijkH, RausJ, StinissenP.Encephalomyelitis-associated antimyelin autoreactivity induced by streptococcal exotoxins. Neurology11: 1433–1441, 2000.
68.
LehmannPV, ForsthuberT, MillerA, SercarzEE. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature358: 155–157, 1992.
69.
SercarzEE, LehmanPV, AmetaniA, BenichouG, MillerA, MoudgilK.Dominance and cripticity of T cell antigenic determinants. Annu Rev Immunol11: 729–766, 1993.
70.
PaliardX, WestSG, LaffertyJA, ClementsJR, KapplerJW, MarrackP, KotzinBL. Evidence for the effects of a superantigen in rheumatoid arthritis. Science253: 325–329, 1991.
71.
HeX, GoronzyJJ, WeyandCM. The repertoire of rheumatoid factor producing B cells in normal subjects and patients with rheumatoid arthritis. Arth Rheum36: 1061–1069, 1993.
72.
KraftM, FilsingerS, KramerKL, KabelitzD, HanschGM, SchoelsM.Synovial fibroblasts as target cells for staphylococcal enterotoxin-induced T-cell cytotoxicity. Immunol93: 20–25, 1998.
KumarV, AzizF, SercarzE, MillerA.Regulatory T cells specific for the same framework 3 region of the Vβ 8.2 chain are involved in the control of collagen II-induced arthritis and experimental allergic encephalomyelitis. J Exp Med185: 1725–1733, 1997.
75.
NagaiH, TakokaY, KamadaH, MoriH.The model of arthritis induced by superantigen in mice. Life Sci55: PL233–PL237, 1994.
76.
SchlievertPM. Role of superantigens in human disease. J Infect Dis167: 997–1002, 1993.
ValdimarssonH, BakerBS, JonsdottirI, PowlesA, FryL.Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens?Immunol Today16: 145–149, 1995.
79.
LeungDY, TraversJB, GiornoR, NorrisDA. Skinner R, Aelion J, Kazemi LV, Kim MH, Trumble AE, Kotb M, Schlievert PM. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest96: 2106–2112, 1995.
80.
ValdimarssonH, SigmundsdottirH, JonsdottirI.Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin?Clin Exp Immunol107(Suppl 1):21–24, 1997.
81.
Watanabe-OhnishiR, AelionJ, LeGrosL, TomaiMA, SokurenkoEV, NewtonD, TakaharaJ, IrinoS, RashedS, KotbM.Characterization of unique human TCR V beta specificities for a family of streptococcal superantigens represented by rheumatogenic serotypes of M potein. J Immunol152::2066–2073, 1994.
EdelmanAS, Zolla-PaznerS.AIDS: A syndrome of immune dys-regulation, dysfunction, and deficiency. FASEB J3: 22–29, 1989.
84.
SchnittmanSM, FauciAS. Human immunodeficiency virus and acquired immunodeficiency syndrome: An update. Adv Intern Med39: 305–355, 1994.
85.
ImbertiL, SottiniA, BettinardiA, PuotiM, PrimiD.Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences. Science254: 860–862, 1991.
86.
LaurenceJ, HodstevAS, PosnettDN. Superantigen implicated in dependence of HIV-1 replication in T cells on TCR Vβ expression. Nature358: 255–258, 1992.
87.
RebaiN, PantaleoG, DemarestJF, CiurliC, SoudeynsH, Adels-bergerJW, VaccarezzaM, WalkerRE, SekalyRP, FauciAS. Analysis of the TCR Vβ repertoire in monozygotic twins discordant for HIV. Proc Natl Acad Sci U S A91: 1529–1533, 1994.
88.
TanabeT, TorresBA, SubramaniamPS, JohnsonHM. Vβ activation by HIV Nef protein: Detection by a simple amplification procedure. Biochem Biophys Res Commun230: 509–513, 1997.
89.
ChirmuleN, OyaizuN, SaxingerC, PahwaS.Nef protein of HIV-1 has B cell stimulatory activity. AIDS8: 733–739, 1994.
90.
StohlW, ElliotJE, LinsleyPS. Human T cell-dependent B cell differentiation induced by staphylococcal superantigens. J Immunol153: 117–127, 1994.
91.
DysonPJ, KnightAM, FairchildS, SimpsonE, TomonariK.Genes encoding ligands for deletion of Vβ11 T cells co-segregate with mouse mammary tumour virus genomes. Nature349: 531–532, 1991.
92.
Franke)WN, RudyC, CoffinJM, HuberBT. 1991. Linkage of Mis genes to endogenous mammary tumor viruses of inbred mice. Nature349: 526–528.
93.
MarrackP, KushnirE, KapplerJ.A maternally inherited superantigen encoded by a mammary tumor virus. Nature349: 524–526, 1991.
94.
WoodlandDL, HappMP, GollubKJ, PalmerE.An endogenous retrovirus mediating deletion of αβ T cells?Nature349: 529–530, 1991.
95.
FestensteinH.Immunogenetic and biological aspects of in vitro lymphocyte allotransformation (MLR) in the mouse. Transplant Rev15: 62–68, 1973.
96.
Acha-OrbeaH, ShakhovAN, ScarpellinoL, KolbE, MullerV, Vessaz-ShawA, FuchsR, BlochingerK, RolliniP, BilloteJ, SarafidouM, MacDonaldHR. Clonal deletion of Vβ14-bearing T cells in mice transgenic for mouse mammary tumor virus. Nature350: 207–211, 1992.
97.
ChoiY, KapplerJW, MarrackP.A superantigen encoded in the open reading frame of the 3' long terminal repeat of mouse mammary tumor virus. Nature350: 203–207, 1992.
98.
DzurisJL, GolovkinaTV, RossSR. Both T and B cells shed infectious mouse mammary tumor virus. J Virol71: 6044–6048, 1997.
99.
GolovkinaTV, DudleyJP, RossSR. Superantigen activity is needed for mouse mammary tumor virus spread within the mammary gland. J Immunol161: 2375–2382, 1998.
100.
IFNβ Multiple Sclerosis Study Group. Interferon IFNβ-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double blind, placebo controlled trial. Neurology43: 655–661, 1993.
101.
DegreM.Influence of exogenous interferon on the peripheral white blood cell count in mice. Int J Cancer14: 699–703, 1974.
102.
FentK, ZbindenG.Toxicity of interferon and interleukin. Trends Pharmacol Sci8: 100–1051987.
103.
SoosJM, SubramaniamPS, HobeikaAC, SchiffenbauerJ, JohnsonHM. The pregnancy recognition hormone, IFN tau, blocks both the development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol155: 2747–2753, 1995.
104.
SoosJM, MujtabaMG, SubramaniamPS, StreitWJ, JohnsonHM. Oral feeding of interferon T can prevent the acute and relapsing forms of experimental allergic encephalomyelitis. J Neuroimmunol75: 43–50, 1997.
105.
MujtabaMG, SoosJM, JohnsonHM. CD4 T suppressor cells mediate interferon tau protection against experimental allergic encephalomyelitis. J Neuroimmunol75: 35–42, 1997.
106.
MujtabaMG, StreitWJ, JohnsonHM. IFN-tau suppresses both the auto-reactive humoral and cellular immune responses and induces stable remission in mice with chronic experimental allergic encephalomyelitis. Cell Immunol186: 94–102, 1998.
107.
MujtabaMG, JohnsonHM. IFNτ inhibits IgE production in a murine model of allergy and in an IgE-producing human myeloma cell line. J Allergy Clin Immunol104: 1037–1044, 1999.
108.
BazerFW, ValletJL, RobertsRM, SharpDC, ThatcherWW. Role of conceptus secretory products in establishment of pregnancy. J Reprod Fertil76: 841–850, 1986.
109.
ImakawaK, AnthonyRV, KezemiM, MarottiKR, PolitesHG, RobertsRM. Interferon-like sequence of ovine trophoblast protein secreted by embryonic trophectoderm. Nature330: 377–379, 1987.
110.
PontzerCH, BazerFW, JohnsonHM. Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1. Cancer Res51: 5304–5307, 1991.
111.
PontzerCH, TorresBA, ValletJL, BazerFW, JohnsonHM. Antiviral activity of the pregnancy recognition hormone ovine trophoblast protein-1. Biochem Biophys Res Commun152: 801–807, 1988.
112.
KhanOA, JiangH, SubramaniamPS, JohnsonHM, Dhib-JalbutSS. Immunomodulating functions of recombinant ovine interferon tau: potential for therapy in multiple sclerosis and autoimmune disorders. Mult Scler4: 63–69, 1998.
113.
PontzerCH, OttTL, BazerFW, JohnsonHM. Structure/function studies with IFN tau: Evidence for multiple active sites. J Interferon Res14: 133–141, 1994.
114.
SubramaniamPS, KhanSA, PontzerCH, JohnsonHM. Differential recognition of the type I interferon receptor by interferons τ and α is responsible for their disparate cytotoxicities. Proc Natl Acad Sci U S A92: 12270–12274, 1995.
115.
WhaleyAE, MekaCS, HarbisonLA, HuntJS, ImakawaK.Identification and cellular localization of unique interferon mRNA from human placenta. J Biol Chem269: 10864–10868, 1994.
116.
FiorentinoDF, BondMW, MosmannTR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J Exp Med170: 2081–2095, 1989.
117.
PerrinGQ, JohnsonHM, SubramaniamPS. Mechanism of interleukin-10 inhibition of T-helper cell activation by superantigen at the level of the cell cycle. Blood93: 208–216, 1999.
118.
SchaefferHJ, WeberMJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol19: 2435–2444, 1999.
